Sarah Lochman
Medical · Des Moines, IANPI 1497382949
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $980 of the $1,096 with a category attached, or 89.5%. It is spread thinly across 25 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.
Across 61 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$204
- Merck$201
- Amgen$111
- Seagen Inc.$104
- Incyte Corporation$54
- AbbVie$48
- plus $373 from 19 others
What the payments were for
- Food & beverage$98089%
- Education$11611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $204 |
| Merck | 10 | $201 |
| Amgen | 8 | $111 |
| Seagen Inc. | 7 | $104 |
| Incyte Corporation | 3 | $54 |
| AbbVie | 2 | $48 |
| Boehringer Ingelheim | 2 | $42 |
| Johnson & Johnson | 2 | $40 |
| Adaptive Biotechnologies Corporation | 2 | $30 |
| AstraZeneca | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Integra Lifesciences Corporation | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Pfizer | 1 | $16 |
| Bioventus LLC | 1 | $16 |
| Insulet Corporation | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| Vertex | 1 | $14 |
| Sanofi | 1 | $14 |
| G1 Therapeutics, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Agios Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,096 in reported general payments places this provider in the 70th percentile of 141 medical providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 20 | $272,630 |
| Lenalidomide | 11 | $138,823 |
| BosulifBosutinib | 12 | $131,630 |
| Imatinib Mesylate | 13 | $3,990 |
| ValacyclovirValacyclovir Hcl | 11 | $2,489 |
| Duloxetine Hcl | 11 | $648 |
| Hydroxyurea | 19 | $403 |
| Letrozole | 12 | $359 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $343 |
| Ondansetron Hcl | 12 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerBosulif | $16 | $131,63012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 141 medical providers in Iowa.
Other medical in Des Moines
- Emily EricksonDes Moines$5K
- Sharon JohnsonDes Moines$786
- Jamie SchumacherDes Moines$707
- Patricia ArasonWest Des Moines$119K
- Maria SonnackIowa City$100K
- Kristin BabbAtlantic$16K
- Laura QuinnetteCouncil Bluffs$14K
- Laurie HughellUrbandale$9K
- Elizabeth McCullochWest Des Moines$6K
- Jordan GreinerPella$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.